Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder

Pharmacology Research Institute

Status and phase: Completed; Phase 2

Conditions: Major Depressive Disorder

Treatments: Drug: Vilazodone

Study type: Interventional

Funder types: Other

Identifiers

NCT00290914

PRI #608

Details and patient eligibility

About

The purpose is to evaluate the safety and usefulness of the investigational drug, vilazodone in depression.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Male or female patients 18-65 years of age, inclusive.